The 146 medicine hospitals in Shaanxi are not sold

On December 9, Shaanxi public resources trading center issued the announcement on the results of drug price adjustment of national organization drug centralized purchase and use pilot to expand regional scope According to the announcement, from 0:00 on December 10, 2019, all kinds of public medical institutions at all levels in Shaanxi Province, military medical institutions in Shaanxi Province who voluntarily participated in the pilot expansion, and medical institutions designated by medical insurance social Office (excluding the pilot city Xi'an), will purchase and sell at the price of 4 + 7 expansion According to the announcement, in the alliance area (non Shaanxi) drug centralized procurement, select the supply varieties, in Xi'an 4 + 7 city drug centralized procurement, confirm that the products supplied to Shaanxi according to the selected price will be purchased online; if the products are not confirmed to be supplied to Shaanxi according to the selected price, they will be directly purchased online, and the price will be negotiated by the medical institutions and online enterprises Interpretation of cypress blue: In the 4 + 7 expansion, the non supplied varieties can also be purchased in Shaanxi If the products not supplied to Shaanxi are confirmed to be supplied to Shaanxi at their own price, they can be purchased online at the same time as the products supplied to Shaanxi; if they are not confirmed, they can be directly online and negotiate with medical institutions directly However, it is not clear here that if the products not supplied to Shaanxi are purchased in Shaanxi, it is necessary for us to continue to study whether they are divided into the share of the belt volume purchase or the share of the rest of the belt volume purchase There is also a problem that there are many non supply products in Shaanxi, of which the price is higher than that of supply products in Shaanxi For example, the median price of rosuvastatin calcium tablets 10mg * 14 for Shaanxi is 4.18 yuan, but the median price of non Shaanxi is 5.6 yuan and 6.84 yuan In this case, if the products not supplied to Shaanxi are purchased on the Internet according to the selected price in Shaanxi, how will the pharmaceutical enterprises and medical institutions balance? According to the announcement, the following conditions shall be met for the varieties that have been evaluated but not selected to be purchased online in Shaanxi: 1 If the price quoted or confirmed by the enterprise is lower than or equal to the "4 + 7 city drug centralized purchase price of Xi'an" and not higher than the "4 + 7 city drug centralized purchase full caliber red price of Shanghai", the price limit will be given Medical institutions and online enterprises can negotiate prices independently, and purchase at or below this price 2 If there is no "4 + 7 city drug centralized purchase price in Xi'an" or "4 + 7 city drug centralized purchase full scale red price in Shanghai", it will be directly linked to the Internet Medical institutions and online enterprises shall negotiate and purchase independently 3 If the price quoted by the enterprise is higher than or does not confirm the "4 + 7 city drug centralized purchase price of Xi'an" and "4 + 7 city drug centralized purchase full scale red price of Shanghai" products, the Internet will be cancelled Interpretation of cypress blue: Different from the previous 4 + 7 volume procurement, Shaanxi 4 + 7 expansion has two red lines for price requirements: 1, "Xi'an 4 + 7 city drug centralized procurement price"; 2, "Shanghai 4 + 7 city drug centralized procurement full caliber red price" Compared with the price of 4 + 7 expansion, these two red lines still have certain advantages But it is undeniable that the price of drugs has been falling again and again If the price reduction is directly proportional to the purchase volume, it is more important for pharmaceutical companies to consider whether they can bear the pressure brought by volume for price According to the announcement, if the evaluated varieties are to be purchased online in Shaanxi, the following conditions shall be met: For products with the same generic name, dosage form and specification, if there are less than three products linked to the Internet through consistency evaluation, if the price quoted or confirmed by the enterprise is lower than or equal to the price of the selected varieties or the price difference calculated in the centralized purchase of drugs in the alliance area (Shaanxi), the price shall be limited and linked to the Internet Medical institutions and online enterprises can negotiate prices independently, and purchase at or below this price In case of the following situations, the network will be removed: 1 For products with the same generic name, dosage form and specification, if there are three or more products that have passed the consistency evaluation, the products that have failed the consistency evaluation shall be removed from the network 2 If the price quoted by the enterprise is higher than the price calculated by the price and difference ratio of the selected varieties in the centralized purchase of drugs in the alliance area (Shaanxi), or if the price is not confirmed, the online listing shall be cancelled Looking at the above announcement, we can see that 146 drugs have been removed from the Internet See the end of the article for details Comments on sapphire blue: According to the opinions on the consistency evaluation of quality and efficacy of generic drugs (GBF [2016] No 8) issued by the general office of the State Council on March 5, 2016, it is clearly required that if more than three manufacturers of the same kind of drugs have passed the consistency evaluation, the varieties that have not passed the consistency evaluation will not be used in the centralized purchase of drugs This means that once the consistency evaluation of this variety has reached three pharmaceutical enterprises, the varieties without consistency evaluation will lose the hospital market According to the requirements of the State Food and drug administration, for generic drugs including essential drug varieties approved for listing before the implementation of the new registration and classification of chemical drugs, the consistency evaluation of the same varieties of other drug manufacturers should be completed within 3 years in principle after the first varieties pass the consistency evaluation With more and more varieties passing the consistency evaluation, the first three-year period after the evaluation is a pressure and a driving force for many pharmaceutical companies to keep moving forward With the issuance of policies and documents for the consistency evaluation of generic drugs, and the promotion of national procurement with volume, many pharmaceutical enterprises have realized that the consistency evaluation of generic drugs is the general trend, not only to be done, but also to be done earlier Attachment: announcement form of withdrawal of online drugs in Shaanxi Province